IMODI, a French consortium
to develop new experimental models of cancer
Meet the needs of the scientific community in R&D of more efficient test systems
Cancer remains a progressive disease with high incidence, mortality and associated costs. The World Health Organization estimates that the cancer mortality will increase by more than 50% between 2002 and 2030, with about 11.5 million deaths in 2030 worldwide.
In this context, IMODI organizes a health industrial sector to meet the needs of the scientific community, whether private or public, in research and development of more efficient test systems to improve the selection of more effective diagnostic and therapeutic agents.
Modeling the diversity of cancers
for effective treatments to each patient
IMODI focuses its activities on 3 major R&D axes
Developing animal models and cell-based assays
Humanizing the tumor microenvironment in mice
Studying the microbiota in cancer patients
Organization
SMEs
Big Pharmas
Academic Institutions
Patient-derived xenografts (PDX)
Immune-humanized mice
Liver-humanized mice
2D/3D Primoculture
Tumor cell lines
Cancer-Associated Fibroblasts
Culture cell medium
Tumor tissues (from PDX)
Tissue Microarray (from PDX)
Plasma (from patients)
Stools (from patients or PDX)
Therapeutic Prediction
PDX data base – MBioLIMS
Predict® proof of concept
Development of innovative bioassays (co-culture…)
In vitro cytotoxicity on patients or PDX-derived cell lines
OncoTRIP® Profiling of tumor sensitivity on primoculture
Translational data analyses
Optimization of drug efficacy and safety
Identification of in silico predictive models
Identification of biomarkers
OncoFlora®
